Preclinical Operations Associate IIRegeneron Pharmaceuticals, Inc.Tarrytown, New York, United States
PB0134 - A novel method for measuring ex vivo intrinsic pathway-triggered thrombin generation in the development of REGN9933, a monoclonal antibody targeting factor XI
Sunday, June 23, 202413:45 – 14:45 ICT
PB0384 - Antibodies against factor XI/factor XIa effectively anticoagulate without increasing bleeding risk in cynomolgus monkeys
